Oruka director receives 9,136 stock options
Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Oruka Therapeutics, Inc. director Samarth Kulkarni received a grant of options covering 9,136 shares of common stock. The options have an exercise price of $55.23 per share and expire on June 1, 2036. According to the footnote, the award vests in equal monthly installments over 12 months starting June 2, 2026.
Insider Trade Summary
Grant/Award: 9,136 shares
Grant/Award
1 txn
Insider
Kulkarni Samarth
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 9,136 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 9,136 contracts (Direct)
Footnotes (1)
- F1. The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.
Key Figures
Options granted: 9,136 options
Exercise price: $55.23 per share
Post-transaction derivative holdings: 9,136 options
+3 more
6 metrics
Options granted
9,136 options
Grant of stock options to director on June 2, 2026
Exercise price
$55.23 per share
Strike price for underlying common stock
Post-transaction derivative holdings
9,136 options
Total options held after reported grant
Grant price
$0.00 per option
Reported transaction price per option on Form 4
Expiration date
June 1, 2036
Option award expiration
Vesting schedule
1/12 monthly from June 2, 2026
Footnote describing vesting of underlying shares
Key Terms
Stock Option (right to buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 55.2300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-01T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
vesting financial
"The option vests as to 1/12 of the underlying shares monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Oruka Therapeutics (ORKA) insider Samarth Kulkarni report on this Form 4?
Samarth Kulkarni reported receiving a grant of stock options for 9,136 shares of Oruka Therapeutics common stock. The options were acquired at a grant price of $0.00 per option, reflecting a typical award structure rather than an open-market purchase.
What is the exercise price of the new Oruka Therapeutics (ORKA) stock options?
The granted options have an exercise price of $55.23 per share for the underlying Oruka Therapeutics common stock. This means Kulkarni can buy shares at $55.23 once the options vest and before they expire, subject to the terms of the award.
How many Oruka Therapeutics (ORKA) options does Samarth Kulkarni hold after this transaction?
After this transaction, Kulkarni holds 9,136 stock options as reported in the Form 4. This figure reflects the total derivative securities following the grant and corresponds to options on 9,136 shares of Oruka Therapeutics common stock.
When do the new Oruka Therapeutics (ORKA) stock options granted to Kulkarni vest?
The option award vests as to 1/12 of the underlying shares monthly starting June 2, 2026. This creates a one-year vesting period during which a portion of the 9,136 options becomes exercisable each month until fully vested.
What is the expiration date of Samarth Kulkarni’s Oruka Therapeutics (ORKA) option grant?
The reported stock options expire on June 1, 2036, if not exercised earlier. After that expiration date, any unexercised portion of the 9,136-share option award will lapse and can no longer be used to acquire Oruka Therapeutics common stock.
Was this Oruka Therapeutics (ORKA) Form 4 transaction an open-market buy or a grant?
The Form 4 describes the transaction as a grant or award acquisition of derivative securities, not an open-market purchase. The transaction code is “A” and the price per option is $0.00, consistent with an option grant from the company.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates